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Abstract: The ability of muscarinic cholinergic receptors
to activate phosphoinositide turnover following agonist-
induced internalization has been investigated. Incubation
of SH-SY5Y neuroblastoma cells with oxotremorine-M
resulted in a time-dependent endocytosis of both musca-
rinic receptors and a subunits of Gq and G11, but not of
isoforms of phosphoinositide-specific phospholipase C,
into a subfraction of smooth endoplasmic reticulum (V1).
Agonist-induced increases in diacylglycerol mass and in32P-phosphatidate labeling, much of which wa of the
tetraenoic species, were also observed in the V
1 fraction,
but these increases persisted when the agonist-induced
translocation of receptors into the V1 fraction was
blocked. All enzymes of the phosphoinositide cycle were
detectable in the V1 fraction. However, with the exception
of phosphatidylinositol 4-kinase, none was enriched
when compared with cell lysates. Both
32P-l beling stu -
ies and enzyme assays point to a very limited capacity
of this fraction to synthesize phosphatidylinositol 4,5-bis-
phosphate, whereas the synthesis of phosphatidylinositol
4-phosphate is robust. These results indicate that endo-
cytosed receptors do not appear to retain their ability to
activate phosphoinositide turnover. The availability of
the substrate for phospholipase C, phosphatidylinositol
4,5-bisphosphate, may be one factor that limits the
activity of muscarinic receptors in this subcellular com-
partment. Key Words: G~q
1ii—PhosphoIipaseC iso-
zymes—Diacylglycerol—Phosphatidylinositol 4- phos-
phate 5-kinase—Lipid substrate availability—Phosphati-
date.
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The internalization (sequestration) of receptors
present at the cell surface into a membrane fraction
that exhibits a lower density than that of the plasma
membrane and is inaccessible to hydrophilic ligands
is an adaptive response to the prolonged agonist occu-
pancy of muscarinic cholinergic receptors (mAChRs)
in neural tissues (Fiegenbaum and El-Fakahany, 1985;
Harden et al., 1985; Thompson and Fisher, 199]). Al-
though the agonist-induced endocytosis of cell surface
receptors via caveolae and/or clathrin-coated pits has
been reported (Garland et al., 1994; Roettger et al.,
1995), results from our laboratory with human SH-
SY5Y neuroblastoma indicate that mAChRs in this
cell line are internalized predominantly via a clathrin-
mediated mechanism (Slowiejko et al., 1996). SH-
SY5Y cells express a relatively high density of
mAChRs (20,000—30,000/cell) of the m3 subtype,
which couple to the G~1111-mediatedactivation of phos-
phoinositide-specific phospholipase C (PLC), with the
subsequent hydrolysis of phosphatidylinositol 4,5-bis-
phosphate (PIP2), formation of inositol 1 ,4,5-trisphos-
phate, and rise in the concentration of intracellular
Ca
2~(Lambert and Nahorski, 1990; Fisher et al., 1994;
Slowiejko et al., 1994). In a previous study with the
parent SK-N-SH cell line, we observed that when inter-
nalized mAChRs were prevented from recycling to the
cell surface by the use of a low-temperature paradigm,
there was a pronounced reduction in the magnitude
of mAChR-stimulated phosphoinositide hydrolysis in
response to the addition of either hydrophilic or lipo-
philic agonists (Thompson and Fisher, 1991). These
results led us to the conclusion that mAChRs localized
at the plasma membrane were preferentially coupled
to PLC activation. One possible explanation for these
results is that the agonist-induced phosphorylation of
cell surface mAChRs (Tobin and Nahorski, 1993;
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Tobin et al., 1996) results in both their internalization
and their uncoupling from PLC. However, the relation-
ship between phosphorylation of the mAChR, receptor
internalization, and functional uncoupling has yet to
be established, and other explanations for the apparent
inability of endocytosed mAChRs to activate PLC need
to be considered. In fact, the issue of whether the inter-
nalization of receptors results in their uncoupling from
PLC remains to be established. In this context, it
should be noted that, in addition to mAChRs, both Gq
and PLC are present in subcellular fractions derived
from the endocytic pathway (Harden et al., 1985;
Martin et al., 1991; Svoboda and Milligan, 1994).
Moreover, in these same fractions, the addition of gua-
nine nucleotides can regulate both PLC activity and
the affinity with which agonists bind to mAChRs
(Harden et al., 1985; Martin et al., 1991). In addition,
dopamine D1, dopamine D2, and adenosine A1 recep-
tors havebeen shown to retain their ability to modulate
adenylyl cyclase activity when present in clathrin-
coated vesicle fractions (Gonzalez-Calero et al., 1990;
Ozaki et al., 1994). Evaluation of whether phosphoino-
sitide-linked receptors can activate PLC at subcellular
locations other than at the plasma membrane is made
difficult by the factthat the extent of agonist-stimulated
PLC activity, even if detectable, is substantially re-
duced when monitored in cell-free preparations. In ad-
dition, to date there has been no systematic study of
the enrichment of the individual components of the
phosphoinositide-signaling pathway (i.e., G~1, PLC,
and the enzymes of phosphoinositide turnover) in the
cellular compartment into which cell surface receptors
are endocytosed.
In the present study, we have addressed the func-
tional status of internalized mAChRs in SH-SY5Y
cells after the isolation of a subcellular fraction (V1)
that is enriched in endocytosed receptors. The follow-
ing questions have been addressed: (1) Do other com-
ponents of the phosphoinositide-signaling pathway
also undergo endocytosis in response to mAChR acti-
vation? (2) Are all of the enzymes necessary for opera-
tion of the phosphoinositide cycle present in this endo-
cytic fraction? The results indicate that although all
enzymes of the phosphoinositide cycle can be detected
in VI, most are not enriched, and the ability of this
fraction to synthesize PIP2 is very limited. However,
the a subunits of Gq and G11 (but not PLC or other
enzymes of phosphoinositide turnover) undergo endo-
cytosis along with the mAChR after exposure of the
cells to muscarinic agonists. Although increases in sn-
1 ,2-diacylglycerol (DAG) mass and [
32PI pho phatidic
acid ([32P] PA) labeling are ob erved in the subcellular
fraction enriched in endocytosed mAChRs, the in-
creases in lipid turnover persist when receptor translo-
cation is blocked. These results suggest that when
mAChRs are endocytosed they lose their ability to
activate PLC and that a determining factor in this loss
of responsiveness may be a limited substrate availabil-
ity. A preliminary account of part of this study has
previously been reported (Sorensen et al., 1997).
MATERIALS AND METHODS
[N-methyl - 3H I Scopolamine methyl chloride ([1H I NMS;
87 Ci/mmol), [3H]scopolamine (74.9 Ci/mmol), [y-32P]-
ATP (6,000 Ci/mmol), [3H]ouabain (49.0 Ci/mmol),
[3H]inositol (110 Ci/mmol), peroxidase-conjugated sheep
anti-mouse lgG, and detection reagents for enhanced chemi-
luminescence (ECL) were purchased from Amersham (Ar-
lington Heights, IL, U.S.A.). [3HlPhosphatidylinositol 4-
phosphate ([3HIPIP; 1 Ci/mmol) was purchased from
American Radiolabeled Chemicals (St. Louis, MO, U.S.A.).
[3HI Quinuclidinyl benzilate ([3H I QNB; 45.4 Ci/mmol)
was obtained from New England Nuclear (Boston, MA,
U.S.A.). Phosphatidylinositol (P1), PIP, DAG, PA, 2’-deox-
ycytidine 5 ‘-triphosphate, ATP, myo-inositol, cytochrome c,
NADPH, atropine, and pilocarpine were obtained from
Sigma Chemical(St. Louis, MO, U.S.A.). 2-Butyn-l-ammo-
nium, N, N,N-trimethyl-4-( 2-oxo- I -pyrrolidinyl) iodide
(oxotremorine-M, Oxo-M) was purchased from Research
Biochemicals International (Natick, MA, U.S.A.). Tissue
culture supplies were purchased from Corning Glass Works
(Corning, NY, U.S.A.) and Sarstedt (Newton. NC, U.S.A.).
Powdered Dulbecco’s modified Eagle’s medium and fetal
calf serum were obtained from GIBCO (Grand Island, NY,
U.S.A.) and BioWhittaker (Walkersville, MD, U.S.A.).
Polyclonal antibodies to PLC-~l,PLC-~3,G,,
501, G1~,G~,
and peroxidase-conjugated goat anti-rabbit lgG were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA,
U.S.A.). Monoclonal anti—PLC-yl was from Upstate Bio-
technology (LakePlacid, NY, U.S.A.). Cardiolipin wasfrom
Avanti Polar Lipids (Alabaster, AL, U.S.A.). Recombinant
DAG kinase (E. coli) was purchased from Calbiochem (La
Jolla, CA, U.S.A.). Cytidine diphosphodiacylglycerol
(CDP-DAG) was obtained from Doosan-Serdary Research
(EnglewoodCliffs, NJ, U.S.A.). 1 -Methyl-3-nitro- I -nitroso-
guanidine was from Aldrich Chemical (Milwaukee, WI.
U.S.A.). Human SH-SYSY neuroblastoma cells were ob-
tainedfrom Dr. June Biedler (Sloan-Kettering Institute, New
York, NY, U.S.A.).
Cell culture conditions
SH-SY5Y cells (passage nos. 68—75) were routinely
grown in tissue culture flasks (75 cm
2/250 ml) in 20 ml
of Dulbecco’s modified Eagle’s medium supplemented with
10% (by volume) fetal calf serum. Cells were grown for 7—
14 days at 37°Cin an atmosphere consisting of 10% CO
2
and 90% humidified air. Cells were isolated after aspiration
of the medium and incubation with a modified Pucks D1
solution (Honneger and Richelson, 1976). Cells were then
resuspended in buffer A (142 mM NaC1, 5.6 mM KC1, 2.2
mM CaCl2, 3.6 mM NaHCO~,1 mM MgCl2, 5.6 mM D-
glucose, and 30 mM HEPES, pH 7.4).
Subcellular fractionation
A modified procedure of the method of Strader et al.
(1984) was used to obtain crude plasma membrane (P1) and
“light” membrane (V1) fractions as previously described
(Slowiejko et al., 1996). The high-speed supernatant frac-
tion (S2) was also retained for assay. In some experiments,
the V1 fraction was applied to a discontinuous density gradi-
ent consisting of 60, 48, and 35% (wt/vol) sucrose and
centrifuged at 150,000 g for 90 mm. Material collecting at
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the 0—35% (V2), 35—48% (V3), and 48—60% (V4) in-
terphases wasremoved, diluted with 10 mM Tris buffer (pH
7.4) containing 1 mM EDTA and centrifuged at 90,000 g
for 90 mm.
Radioligand binding
Whole cell lysates and subcellular fractions of SH-SY5Y
cells were resuspended in KGEH buffer (139mM potassium
glutamate, 4 mM MgCI2, 10 mM EGTA, and 30 mM
HEPES, pH 7.4). Fractions were then incubated with either
6 nM [
3H]NMS, I nM [3H]QNB, or 6 nM [3Hiscop-
olamine at 37°Cfor 90 mm. These concentrations of radioli-
gands are sufficient to occupy >90% of mAChR sites in
lysates and subcellular fractions. Nonspecific binding was
determined as that unaffected by inclusion of 25 ~sMatro-
pine. Reactions were rapidly terminated by filtration through
Whatman GF/B glass—fiberfilters and radioactivity was de-
termined after the addition of 5 ml of Universol scintillation
fluid.
Sodium dodecyl sulfate—polyacrylamide gel
electrophoresis (SDS-PAGE)
Aliquots (25 ~.tg)of whole cell lysates or subcellular frac-
tions of SH-SY5Y cells were boiled in SDS-PAGE sample
buffer for 5 mm and electrophoresed through 10% SDS-
polyacrylamide gels (Laemmli, 1970). Proteins were trans-
ferred to polyvinylidene fluoride (PVDF) membranes
(Millipore, Bedford, MA, U.S.A.) and processed for immu-
noblot analysis. It should be noted that the separation of
someprotein isoforms (including G,~
1and ~ is facilitated
by the presence of sodium tetradecyl sulfate present in com-
mercially available SDS (see Siegel and Desmond, 1989).
Western blot analysis
Nonspecific binding sites were blocked in phosphate-buf-
fered saline (pH 7.4) containing 0.1% Tween 20 (PBS-T)
and 1% bovine serum albumin for 1 h at room temperature.
Primary antibodies were diluted in blocking solution (final
concentration, 0.1—0.5 ,ug/m]) and incubated with the mem-
branes for 1 h. Excess primary antibody was removed by
washing the membranes three times in PBS-T. The blots
were then incubated in the appropriate peroxidase-conju-
gated secondary antibody diluted in PBS-T (1:10,000) for
I h and subsequently washed three more times in PBS-T.
Immunoreactive proteins were detected by ECL. Membranes
were reprobed after stripping in 0.1 M Tris-HC1 (pH 8.0),
2% SDS, and 100 mM ~-mercaptoethanol for 30 mm at
52°C.The blots were rinsed two times in PBS-T and pro-
cessed as above with a different primary antibody. Quantita-
tive analysis of autoluminograms was performed by com-
puter-assisted imaging densitometry (MCID, Imaging Re-
search, St. Catharines, Ontario, Canada). The assignment of
specific bands as G~qand G~11,which were detected with




1 and V1 fractions (100—400 ~ig of protein)
were resuspended in 150 ~tl of KGEH buffer (free Ca
2~,50
nM). Reactions were initiated by the addition of 100 ~il
[22PIATP (final concentration, 50 tiM; sp. act. 2.5—4.5
x l0~cpm/nmol) and allowed to continue for the times
indicated (0—5 mm at 37°C).In some experiments, the con-
centration of ATP was increased to 200 ftM to ensure that
its availability was not a rate-limiting factor. Reactions were
terminated by the addition of 0.75 ml CFICI
2/CH3OH (1:2).
Lipids were extracted, separated, and quantitated as pre-
viously described (Fisher et al., 1984).
Argentation TLC
PA formed from the
32P-phospholipid-labeling experiment
was isolated and extracted from the silicagel with three 1.0-
ml aliquots of CHCl
3/CH~OH/HCl(1:2:0.05). The com-
bined extracts were washed with 2.0 ml CHC11/CH3OH/
H2O (3:48:47) and blown to dryness under N2. PA was
methylated with excess diazomethane (Fales et al., 1973)
and separated according to degree of unsaturation on 40%
(wt/wt) silver nitrate—impregnated TLC plates as outlined
by Van Rooijen et al. (1985).
DAG mass
The mass of DAG present in aliquots of intact cells and
Pi or V1 fractions (100—300 pg of protein) was monitored
by the method of Preiss et al. (1986), after initial lipid
extraction (Fisher and Agranoff, 1980). DAG standards
(100—1,000 pmol) were routinely run in parallel.
DAG kinase
Activity was monitored by the method of Besterman et
al. (1986), with the exceptions that the incubation time was
reduced to 2 mm and the concentration of ATP increased to
300 1iM.
PLC
Activity was monitored using [
3H]PIP as substrate.
Assays were performed in a final volume of 100 ~.clcon-
taining 10 mM HEPES (pH 7.4), 120 mM KCI, 10 mM
NaC1, 2 mM EGTA, 2.2 mM CaC1,, 6.0 mM MgC1
2, and
0.5% sodium cholate. The final concentration of [
2HIPIP
was 50 fLM (~-20,000dpm) and the lipid was added after
having been blown down under N
2 and sonicated in 10 mM
HEPES (pH 7.4) buffer. Reactions were allowed to proceed
for 5 mm at 30°Cand were terminated by the addition of
0.375 ml CHCl~/CH~OH/HCl(20:40:1), followed by 0.125
ml CHCI3 and 0.125 ml 0.1 M HCI. Radioactivity was then
quantitated after the addition of 5 ml of Universol scintilla-
tion fluid to a 0.2-ml aliquot of the upper phase.
CDP-DAG synthase
Activity was measured as previously described by Spar-
row and Raetz (1985) and Kelley and Carman(1987). Ali-
quots of whole cell lysates, and P1 or V1 fractions (40—100
pg of protein), were incubated for 10 mm at 37°Cin 50mM
Tris-maleate buffer (pH 6.5), 1 mM PA, 20 mM MgCI2, 1
mg/mi bovine serum albumin, and 1 mM [y-
32PIdCTP
(22,000 cpmlninol) in final volume of 200 p1. Reactions
were terminated by the addition of 1.7 ml CHCl~/CH
3OH
(1:2) and lipids extracted after the addition of 0.5 ml 1.2 M
HC1 and 1.0 ml CHCI5. The lower phase was washed twice
with 2 ml of acidified Foich upper phase and radioactivity
present in I .0-mi aliquots of the organic phase determined.
P1 synthase
Activity was monitored by the method of Fischl and Car-
man (1983), as modified by Heacock et al. (1993), with
the exceptions that MnC12 wasexcluded and thefinal concen-
tration of inositol was 1 mM (22,000 cpm/nmol).
P1 and PIP kinase
Activities were measured as previouslydescribed by Mac-
Donald et al. (1987).
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Other measurements
NADPH—cytochrome c reductase activity was measured
spectrophotometrically at room temperature by the method
of Sotocassa et al. (1967). [3HlOuabainbinding was deter-mined by the method of Svoboda and Milligan (1994). Pro-
tein content was measured with the Pierce BCA protein assay
reagent (Rockford, IL, U.S.A.).
Data analysis
Results given are mean ± SEM values for the number
(n) of separate experiments performed. For every parameter
monitored, duplicate or triplicate replicates were obtained.
Student’s two-tailed t tests were used to evaluate the statisti-
cal differences of the means of paired or unpaired sets of
data.
RESULTS
Agonist-induced subcellular redistribution of cell
surface mAChRs
Evaluation of the functional status of internalized
mAChRs required the isolation of a subcellular fraction
from SH-SY5Y cells in which sequestered mAChRs
were concentrated and one that yielded sufficient mate-
rial for biochemical studies. Initial attempts to obtain
such a fraction after the application of hypotonic cell
lysates to continuous or discontinuous sucrose density
gradients were unsuccessful due to the limited degree
of enrichment of mAChRs obtained in any single frac-
tion. A more effective separation of internalized
mAChRs was obtained using a modification of the
differential centrifugation procedure of Strader et al.
(1984). Using this approach, a redistribution of
mAChRs from a crude plasma membrane fraction (P
1)
into a light vesicular fraction (V1), which sedimented
at 200,000 g for 90 mm was observed when intact SH-
SY5Y cells were incubated with Oxo-M for 30 mm at
37°C.Whereas only 3% of total mAChRs recovered
were located in the V1 fraction obtained from quiescent
cells, this value increased to 16% upon exposure of
cells to Oxo-M (500 ±73% of control, n = 5, Table
1). This appearance of mAChR binding sites in the
V1 fraction was accompanied by a corresponding loss
of [
3H}QNB binding sites from the P
1 fraction. Marker
analysis indicated that <2% of [
3Hjou bain binding
(a measure of plasma membrane Na~,K~-ATPase)
was recovered in the V
1 fraction and that this distribu-
tion was unaltered by the addition of agonist. Although
the P1 fraction possessed the majority of the NADPH—
cytochrome c reductase activity (a marker for smooth
endoplasmic reticulum; Table I), significant amounts
of this enzyme (35—41%) were recovered in the V1
fraction, indicating that the latter represents, in part at
least, a subfraction of the smooth endoplasmic reticu-
lum. No subcellular redistribution of NADPH—cyto-
chrome c reductase activity occurred after exposure of
the cells to Oxo-M. In some experiments, the V1 frac-
tion was applied to a discontinuous sucrose gradient
consisting of 35, 48, and 60% sucrose and centrifuged
at 150,000 g for 90 mm to further fractionate V1. After
density gradient centrifugation, >90% of mAChRs and
protein recovered were located at the 0—35% sucrose
interface (V2), an equilibrium density at which inter-
nalized mAChRs, /32-adrenergic, and transferrin recep-
tors have previously been observed (Harden et al.,
1985; Lohse et al., 1990; Sillence and Downes, 1993).
Because the agonist-induced increases in mAChR den-
sity in the V2 fraction obtained from SH-SY5Y cells
(430—650% of control) were comparable with those
observed for the V1 fraction (see Table 1), the latter
was used for all subsequent experiments.
In intact cells, when monitored as the loss of [
3HI-
NMS binding sites, 30—40% of cell surface mAChRs
are sequestered upon the addition of Oxo-M (Slow-
iejko et al., 1996), whereas <20% of receptors are
recovered in the V
1 fraction by using the fractionation
paradigm. Thus, to determine whether the subcellular
redistribution of mAChRs into the V1 fraction was
TABLE 1. Subcellular distribution of mAChRs and marker enzymes in control and Oxo-M—stimulated cells
Specific activity
of lysate
Percentage of total recovered
P1 V1 S2 % of recovery
Control
[
3H]QNB binding (fmol/mg of protein) 289 ±82 97 ± 1 3 ± 1 ND 84 ±6
3H]Ouabain binding (pmol/mg of protein) 2.33 ±0.16 98 ± I 2 ± I ND 82 ± 13
NADPH—cytochrome c reductase (nmol/mg of protein/mm) 7.5 ±0.7 65 ±2 35 ±2 ND 106 ±13
Protein — 48 ±1 19 ±1 33 ±1 103 ±3
Oxo-M
[3HIQNB binding (fmol/mg of protein) 262 ±72 84 ±2” 16 ±2” ND 79 ±4
3HlOuabain binding (pmol/mg of protein) 2.38 ±0.17 98 ± 1 2 ± I ND 74 ± 14
NADPH—cytochrome c reductase (nmol/mg of protein/mm) 7.3 ±0.97 59 ±2 41 ±2 ND 114 ±15
Protein — 46 ±2 21 ±2 35 ±2 96 ±7
SH-SY5Y cells (—100 mg of protein) were incubated in the absence (Control) or the presence (Oxo-M) of 1 mM Oxo-M for 30 mm and
then hypotonically lysed and fractionated as described in Materials and Methods. Cell lysates, P
1, V1, and S2 fractions were assayed for
[
3H]QNB, [3Hlouabain binding, protein content, and NADPH—cytochrome c reductase activity. Results shown are mean ±SEM v lu s
four or five separate experiments. ND, not detectable.
Different from control, p < 0.05.
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representative of sequestration events monitored in in-
tact cells, the characteristics of this agonist-mediated
translocation of mAChRs were further examined. The
appearance of mAChRs in the V1 fraction was time
dependent with the onset detectable within 5 mm of
Oxo-M addition and the maximal effect observed after
30—60 mm (t112 = 12 mm; Fig. IA), results compara-
ble with those previously observed for receptor seques-
tration in intact SH-SY5Y cells (Fisher et al., 1994;
Slowiejko et al., 1994). The appearance of mAChRs
in the V1 fraction also displayed a similar dependence
on agonist concentration and efficacy to that observed
for sequestration in intact cells. Thus, half-maximal
translocation was observed at a 3—10 1.jM concentra-
tion of Oxo-M (data not shown), and addition of the
partial agonist pilocarpine (1 mM) elicited a signifi-
cantly smaller redistribution of mAChRs than that ob-
served for Oxo-M (139 ±3% of control, n = 4; Fig.
IA). Receptors recovered in the V1 fraction after Oxo-
M addition were differentially recognized by musca-
rinic antagonists. The lipophilic ligands [
3H1QNB and
[3HIscopolamine consistently detected more mAChR
sites than the hydrophilic ligand [3H]NMS, even when
FIG. 1. Oxo-M pretreatment of SH-SY5Y cells results in the
translocation of mAChRs into the V
1 fraction. A: SH-SY5Y cells
were preincubated with either buffer A (0), 1 mM pilocarpine
(A), or 1 mM Oxo-M (•) at 37°Cfor the times indicated, the
reactions terminated by the addition of ice-cold buffer A and the
V1 fractions obtained from hypotonic cell lysates as described
in Materials and Methods. mAChRs present in the V1 fraction
were then monitored by means of [
3H]QNB bi ding. alues are
express d as the specific binding of [3H]QNB (percentage of
zero time values). Results shown are mean ±SEM values for
three or four separate experiments. B: Cells were preincubated
with 1 mM Oxo-M for 30 mm and the V
1 fraction isolated after
cell lysis and differential centrifugation. The specific binding of
[
3H]QNB, [3H]NMS, and [3Hlscopolamine to mAChRs in the V
1
fraction was then measured. Values are expressed as specific
binding (percentage of zero time values). Results shown are
mean ±SEM values for four separate experiments. *Different
from Oxo-M, p < 0.05; °°differentfrom either [
3H]QNB or [3Hl-
scopolamine binding, p < 0.05.
FIG. 2. Western blot analysis of the a subunits of Gq, G
11, and
G, and of G11 in subcellular fractions derived from control or
Oxo-M—pretreated cells. A: Suspensions of SH-SY5Y cells were
incubated in the presence of either buffer A(—) or 1 mM Oxo-
M (+) for 30 mm, the cells lysed, and subcellular fractions iso-
lated as described in Materials and Methods (Lys = whole cell
lysates). Equivalent aliquots (25 pg) of cellular protein from
whole cell lysates or subcellular fractions were electrophoresed
through 10% SDS-polyacrylamide gels and transferred to PVDF
membranes. Membranes were then immunoblotted for ~
G,,11, G,,~,or G11 (at primary antibody concentrations of 0.5 jig!
ml for G,,q/G~iiand G,,~and 0.1 pg/mI for G~)as described in
Materials and Methods. Results shown are representative of
those obtained in four separate experiments. B: SH-SY5Y cells,
grown in culture dishes, were incubated either in the absence
(control) or presence of 1 mM Oxo-M for 24—48 h. Cells were
then lysed and 25-pg aliquots taken for SDS-PAGE and western
blot analysis. Results shown are representative of those obtained
in four separate experiments. [
3H]QNB binding in Oxo-M—
treated cells was reduced by 52 ±4% under these conditions
(n = 4).
assayed at 37°C (Fig. IB). Taken collectively, the
results indicate that although fewer mAChRs are re-
covered in the V
1 fraction than are “lost” from the
surface of intact SH-SY5Y cells, the characteristics of
mAChR translocation into the V1 fraction resemble
those observed for receptor sequestration in intact cells
in terms of kinetics, agonist concentration dependence,
and agonist efficacy. Furthermore, it is apparent that
the V1 fraction is enriched in endocytosed mAChRs
that are readily recognized by lipophilic, but not hydro-
philic, ligands.
G,~qand G~11are endocytosed with the mAChR
The subcellular distribution of G0~10 and Gu, in
control and Oxo-M—pretreated cells was determined
by western blot analysis and quantitative densitometry
(Fig. 2A). In control cells, all three subunits analyzed
were significantly enriched in the P1 fraction compared
with whole cell lysates (359 ±50, 236 ±7, and 219
±31%, for G04, G~11,and G~,respectively, n = 4).
In contrast, there was little immunoreactivity associ-
ated with G,,~1,G011, orG~,in the V1 fraction (13 ±6,
11 ±5, and 21 ±9% of lysate values, respectively, n
= 4). The a subunits of all three G proteins were
essentially absent from the S2 fraction. Prior exposure
of the cells to Oxo-M for 30 mm resulted in an increase
in Goq and Gu11 immunoreactivity in the V1 fraction
J. Ncuroche,n., Vol. 68. No. 4, 1997
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Rd ative specific activity PercenltIge of total recovered
% of
recoveryP
1 V1 S~ P1 V1 S2
PLC
Control 6.63 ±1.52 0.72 ±0.14 0.29 ±0.09 2.64 ±0.37 19 ±4 4 ± 1 77 ±6 114 ±6
Oxo-M 7.97 ±2.79 0.75 ±0.25 0.42 ±0.10 2.59 ±0.46 19 ±4 5 ± I 76 ±4 119 ±10
DAD kinasc
Control 1)57 ±t).06 (1.36 ±0.08 0.58 ±0.05 1.37 ±0.30 27 ±7 16 ±2 57 ±10 69 ±7
Oxo-M 0.62 ±0.03 0.45 ±0.09 0.59 ±0.10 1.42 ±0.23 26 ±7 15 ±3 58 ±9 67 ±3
CDP-DAG synthase
Control 1.39 ±0.16 1.50 ±0.19 0.81 ±0.05 0.04 ±0.01 SI ±2 17 ±2 2 ±0 97 ± II
Oxo-M 1.34 ±0.21 1.60 ±0.38 0.93 ±0.05 0.03 ±0.01 78 ±2 21 ±2 2 ±0 90 ±8
P1 synthase
Control 0.68 ±0.28 2.02 ±0.19 0.73 ±0.15 0.02 ±0.01 86 ±2 13 ±3 2 ± 1 116 ±4
Oxo~M 0.62 ±0.27 2.31 ±t).42 0.86 ±0.17 0.02 ±0.01 85 ±4 13 ±5 2 ± I 123 ±27
P1 kinase
Control 0.58 ±0.12 1.05 ±0.16 2.21 ±0.19 0.42 ±0.07 49 ±2 39 ± 1 12 ±2 103 ± 10
Oxo-M 0.59 ±0.12 1.27 ±(1.15 2.09 ±0.15 0.41 ±t).06 50 ±3 37 ±2 13 ±3 101 ±7
PIP kinase
Control 0.06 ±0.02 1.47 ±0.22 0.40 ±0.08 0.67 ±0.36 67 ±8 12 ±3 21 ± II 80 ± Il
Oxo-M 0.04 ±0.02 1.74 ±0.14 0.59 ±0.10 0.58 ±0.28 67 ±6 14 ±3 19 ±8 85 ±6
SH-SY5Y cells were incubated in the absence or presence of I mM Oxo-M for 30 mm and then sub jccted to hypotonic lysis and differential
centritugation. Cell lysates, P1. V~,and S2 fractions were then assayed for enzyme activity. Results shown are mean ±SEM values for three
to live separate experiments. Relative specific activity = aclivity of enzyme in a subcellular fraction/activity of enzyme in whole cell lysate.
(177 ± 35 and 201 ± 60% of control, respectively, n
= 4, p <0.05) and a 14—15% decrease in P1 immuno-
reactivity. In contrast, no reduction in immunoreactiv-
ity of G,,~1and G,~11was detected in whole cell lysates
obtained from cells incubated with Oxo-M. In addition,
no increase in G,,. immunoreactivity in the V1 fraction
was observed after agonist pretreatment. To further
evaluate the specificity of Oxo-M—induced changes in
G,,~11,~11and Gu5, intact cells were incubated with Oxo-
M for 24—48 h. Under these conditions, immunoreac-
tivity of Guq and Gu11 in whole cell lysates was reduced
by 71 ± 16 and 49 ±16%, respectively (n = 4). In
contrast, a significantly smaller decrease in G,~,immu-
noreactivity (26 ± 7%) was observed (Fig. 2B). The
distribution of G4 was also determined in the subcellu-
lar fractions. Although the P1 fraction was the most
enriched compared with cell lysates (166 ± 8%, n
= 5), significant immunoreactivity was also associated
with the V1 fraction (68 ± 3%, n = 5). No increase
in G~immunoreactmvity in the V1 fraction was observed
after exposure of the cells to Oxo-M for 30 mm.
Subcellular distribution of PLC isozymes
PLC present in intact cells and subcellular fractions
was determined either by means of measurement of
the release of labeled inositol phosphates or after west-
ern blot analysis and quantitative densitometry. When
assessed using exogenously added [
3HIPIP as sub-
strate, most of the PLC activity (76—77%) was recov-
ered in the S
2 fraction with much less activity localized
to the P1 fraction (19%). Five percent or less of PLC
activity was recovered in the V1 fraction (relative sp.
act. 0.29—0.42; Table 2). No significant changes in
the activity or distribution of PLC occurred after Oxo-
M pretreatment. Because individual PLC isozymes
may be differentially localized within the cell, the sub-
cellular distributions of PLC-N I (primarily a~1-linked),
PLC-~3(a~1and ny-linked), and PLC-yI (linked to
receptor tyrosine kinases) were evaluated by western
blot analysis (Fig. 3). PLC-~lwas enriched in the P
fraction (180 ±22% of that present in cell lysate, n
= 4) but not in either the V1 or the S2 fractions (50
± 4 and 11 ± 3%, respectively, n = 3). PLC-~3was
significantly more enriched in the V fraction (210
± 31% of that present in cell lysates, n = 5) than in
the P1 fraction (125 ±11%, n = 5), whereas much
less immunoreactivity was observed in the S2 fraction
(27 ± 2%, n = 5). In contrast, PLC-yl was most
enriched in the S2 fraction (677 ±64% of cell lysate,
n = 3). PLC-’yl immunoreactivity in the V1 fraction
equaled that present in the cell lysate (120 ± 35%, n
= 3) but was virtually absent from the P1 fraction (10
FIG. 3. Western blot analysis of PLC-~31,PLC-~33,and PLC-y1
in subcellular fractions derived from control or Oxo-M—pre-
treated cells. Experimental conditions were as described in the
legend to Fig. 2A and antibodies to PLC-/Il, PLC-/I3, and PLC-
yl were used at final concentrations of 0.25, 0.1, and 0.1 jig!
ml, respectively. Results shown are representative of those ob-
tamed in three or four separate experiments.
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±5% of cell lysate, n = 4). No statistically significant
changes in the subcellular distribution of either PLC-
~31or yl were detected in response to Oxo-M pretreat-
ment of cells, whereas a small but statistically signifi-
cant reduction (14%) in the distribution of PLC-f33
was observed for the V1 fraction (Fig. 3).
DAG availability, PA formation, and metabolism
After the activation of PLC-linked receptors in intact
cells, increases in DAG availability and PA formation
are consistently observed. To determine whether these
changes are also evident in the cellular compartment
enriched in endocytosed mAChRs, DAG mass and PA
formation were monitored in subcellular fractions ob-
tained from both control and Oxo-M--treated cells. The
concentration of DAG in the V1 fraction obtained from
control cells was relatively low (24% of that present
in the P1 fraction, see Table 3). When the same V1
fraction was incubated in an “intracellular-like”
KGEH buffer that contained [
32P]ATP, the [32P]PA
labeling observed was also <20% of that obtained
for the P
1 fraction (Fig. 4A). The relatively limited
synthesis of [
32P]PA in the V
1 fraction can be attrib-
FIG. 4. [
32P]PA labeling in subcellular fractions derived from
control or Oxo-M—pretreated cells. SH-SY5Y cells were preincu-
bated with either buffer A or 1 mM Oxo-M for 30 mm before cell
lysis and fractionation. A: Either V
1 (s) or P1 (0) fractions from
control cells were incubated in KGEH buffer and [
32P]ATP for
the times indicat d. Reactions were terminated by the addition
of CHCI
3/CH3OH (1:2) and lipids extracted and separated as
described in Materials and Methods. Results shown are repre-
sentative of those obtained in three separate experiments and
are mean values of triplicate replicates. B: The increases in
[
32PJPA labeling observed in P
1 and V1 fractions after the Oxo-
M pretreatment were monitored (2-mm incubation period). Val-
ues are expressed as PA labeling (percentage) relative to control
cells (buffer A pretreatment). Results shown are mean ±SEM
values for 11 separate experiments. °Different from control, p
<0.05; °°differentfrom the P1 values, p < 0.05. In some studies,
the concentration of ATP was increased from 50 to 200 pM,
with no change in relative labeling patterns (see Materials and
Methods).
TABLE 3. DAG concentration.s in intact cells and
suhcellular fraction.v derived from control
and Oxo-M—stimulated cells
DAD mass (nmol/mg of protein)
Intact cells P V~
Control 2.12 ±0.40 5.58 ±0.45 1.35 ±0.12
Oxo-M 3.31 ±0.60” 8.81 ±0.88” 2.39 ±0.34”
Percentage of control 161 ± IS 160 ± 13 176 ± II
SH-SY5Y cells were incubated for 30 mm in the absence or
presence of I mM Oxo-M. Cells were then lysed and subjected to
differential centrifugation. Aliquots of either intact cells or P~or V1
fractions were then assayed for DAD mass, as described in MaterIals
and Methods. Results shown are means ±SEM for four separate
experiments.
Different from control, p < (1.05.
uted to the restricted availability of DAG, rather than
a low activity of DAG kinase, because both P1 and V1
fractions possessed similar activities of this enzyme
(Table 2). To determine the molecular species of PA
formed (and hence, the source of DAG backbone),
the
32P I PA was methylated and subjected to argenta-
ion TLC (Van Rooijen et al., 1985; see Fig. 5). Under
basal conditions, much of the [32P]PA label (in both
V
1 and P1 fractions) was present in the mono- and
dienoic forms, whereas <20% was recovered in the
tetraenoic species (indicative of an inositide origin).
When the cells were exposed to Oxo-M, significant
increases in the concentration of DAG were observed
in intact cells and P1 and V1 fractions (Table 3). The
attendant increase in [
32PIPA labeling, which was
most evide t for the V
1 fraction (212 ±20% of control,
n = 11), reflected this increased availability of DAG
(Fig. 4B). Analysis of the newly formed [
22P]PA indi-
cated that approximately half was of the mono- and
dienoic species, with the remainder recovered as either
the tetra- or pentaenoic species. Increases in the label-
ing of the tetraenoic species of PA were significantly
greater in the V
1 fraction (680 ± 29%) than in the P1
fraction (385 ±26% of control,p < 0.05). In contrast,
no significant differences in the labeling of the other
molecular species of PA in the P1 and V1 fractions
were observed (Fig. 5). The V1 fraction also possesses
the potential for the further conversion of PA into
CDP-DAG, because CDP-DAG synthase activity was
detected in this fraction (Table 2).
To determine whether the agonist-mediated increase
in DAG accumulation and PA formation reflected the
activation of mAChRs that had been endocytosed into
the V1 fraction, cells were made hypertonic (600
mOsm) by the addition of sucrose, a condition under
which the agonist-induced translocation of mAChRs
is essentially abolished (Fig. 6; see Slowiejko Ct al.,
1996). However, pretreatment of cells with Oxo-M
under hypertonic conditions still resulted in robust in-
creases in [
32P]PA labeling (Fig. 6). Further evidence
to indicate that the receptor-mediated changes in DAG
j. Neurochem., Vol. 68, No. 4, 1997
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FIG. 5. Species of [32PIPAlabeled in P1 or V1 frac-
tions obtained from control or Oxo-M—pretreated
cells. Cells were incubated for 30 mm at 37°Cin either
the absence (—) or presence (+) of 1 mM Oxo-M.
Cells were then lysed and subcellular fractions pre-
pared. P1 and V1 fractions were incubated with [
32P]-
ATP and the labeled PA isolated and extracted. PA
was then methylated with diazomethane and sub-
jected to argentation TLC (see Materials and Meth-
ods). The autoradiographic pattern of the species of
{32P] PA labeled is shown and is representative of
three experiments performed. Results are expressed
as 32P labeling of each species of PA observed after
agonist pretreatment (percentage of controls; mean
±SEM, n = 3). *Different from corresponding value
in P
1 fraction.
concentration and PA formation do not result from
activation of mAChRs within the V1 fraction was ob-
tained from determination of the kinetics of the two
responses. Whereas the t112 for mAChR translocation
is -=12 mm (Fig. 1A), the corresponding value for the
increase of [
32PIPAlab ling i 2—3 mm (data not
shown). Thus, the signaling response in the V
1 fraction
(as monitored by the formation of [
32PJPA) o curs
before and independently of the endocytosis of the
mAChR.
Inositol lipid substrate availability
Whether the availability of inositol lipid substrate
is a factor that limits the ability of endocytosed
mAChRs to activate PLC was assessed by 32P-meta-
bolic labeling studies and by direct measurement of the
relevant enzyme activities. When P
1 and V1 fractions
obtained from control SH-SY5Y cells were incubated
in KGEH buffer with [
32P]ATP, >70% of the radiola-
bel present in the lipid fraction was recovered in PIP
2
and PIP at all incubation times. However, pronounced
differences in the
32P-labeling of the polyphosphoinosi-
FIG. 6. Agonist-induced mAChR translocation and
increased [32P]PA labeling are distinct events. SH-
SY5Y cells were incubated under either isotonic (325
mOsm:lso) or hypertonic (600 mOsm:Hyper) condi-
tions in either theabsence or presence or 1 mM Oxo-
M beforecell lysis and fractionation. V
1 fractions were
monitored for either [
3H]QNBbinding or [32P]PAla-
beling. Results are expressed aseither [3HJQNBbind-
ing or [32PIPAlabeling (percentage of controls).
tides were observed for the two subcellular fractions.
In particular, PIP
2 was poorly labeled in the V1 fraction
(16 ±2% of that observed for the P1 fraction at 2 mm,
n = fm,p < 0.05; Fig. 7A). In contrast, [
32P]PIP label-
ing in the V
1 fraction exceeded that observed for the
P1 fraction (139 ± 13% at 2 mm, n = 6; Fig. 7B).
Prior exposure of the cells to Oxo-M resulted in a
significant reduction in the subsequent
32P-labeling of
both PIP and PIP




1 fraction (Fig. 7C). Consistent with the observa-
tions made from the metabolic labeling studies, there
were pronounced differences in the subcellular distri-
bution of three key enzymes of inositol lipid synthesis,
namely, P1 synthase, P1 kinase, and PIP kinase (Table
2). Neither P1 synthase nor PIP kinase was enriched
in the V1 fraction (relative sp. act. -=0.8 and 0.50,
respectively), both of these enzymes being recovered
predominantly in the P1 fraction. In marked contrast,
37—39% of P1 kinase activity recovered was present in
the V1 fraction (relative sp. act. ‘—2.2), an observation
consistent with the enhanced
32P-labeling of PIP in this
.1. Neurochem., Vol. 68, No. 4, 1997
mAChR ENDOCYTOSIS AND INOSITOL LIPID TURNOVER 1481
FIG. 7. Polyphosphoinositide labeling in subcellu-
lar fractions derived from control or Oxo-M—pre-
treated cells. SH-SY5Y cells were preincubated
with either buffer A or 1 mM Oxo-M for 30 mm
before cell lysis and fractionation. A and B: Either
V~(s) or P1 (0) fractions from control cells were
incubated in KGEH buffer and [
32P]ATPfor th
times in icated. Reactions were terminated by the
addition of CHCI
3/CH3OH (1:2) and lipids extracted
and separatedas described in Materials and Meth-
ods. Results shown are representative of three sep-
arate experiments, and are mean values of triplicate




PIP observed in P
1 and V1 fractions after Oxo-M
pretreatment were monitored (2-mm incubation pe-
riod). Valuesareexpressed as [
32P]PIP or [32PlPIP
2
labeling observed after agonist pretreatment (per-
centage of controls; mean ±SEM, n = 9). °Differentfrom control, p < 0.05. In some experiments, the concentration of ATP used in
the assays was increased from 50 to 200 pM, without any difference in the relative labeling of individual lipids (see Materials and
Methods).
fraction. No changes in the amount or distribution of
enzyme activities were observed after the pretreatment
of cells with Oxo-M (Table 2).
DISCUSSION
In the present study, evaluation of a possible func-
tional role for internalized mAChRs in SH-SY5Y cells
has been facilitated by the isolation of a subcellular
fraction (V1) that is enriched in endocytosed receptors.
Previously, a “light vesicle” fraction obtained after
density gradient centrifugation of whole cell lysates
has been used to monitor the subcellular localization
of internalized cell surface receptors (Waldo et al.,
1983; Harden et al., 1985; Lohse et al., 1990; Sillence
and Downes, 1993; Svoboda and Milligan, 1994). Al-
though both the V1 and light vesicle fractions are het-
erogeneous, the use of a differential centrifugation pro-
cedure to obtain V1 results in the isolation of an endo-
cytic fraction that is recovered more rapidly and in
better yield. Moreover, the characteristics of the V1
fraction and light vesicle fractions are similar. For ex-
ample, the V1 fraction (1) demonstrates a comparable
degree of enrichment of mAChRs (four- to fivefold)
upon agonist addition, (2) is enriched in smooth endo-
plasmic reticulum, (3) is essentially devoid of plasma
membrane, and (4) exhibits similar equilibrium den-
sity characteristics as the light vesicular fraction when
applied to sucrose density gradients. In addition, ra-
dioligand binding studies indicate that mAChRs in the
V1 fraction are relatively inaccessible to hydrophilic
ligands, which suggests that receptors are present in
endocytic “inside-out” vesicles. Although fewer
mAChRs are recovered in the V1 fraction than are lost
from the cell surface of intact cells, the characteristics
of mAChR translocation into this subcellular fraction
resemble those observed for receptor sequestration in
intact cells in terms of kinetics and dependence on
agonist concentration and efficacy.
For internalized mAChRs to activate PLC, both G~1
and PLC must be present in the same endosomal com-
partment. Although relatively little G011 and G,~11are
present in the V1 fraction obtained from quiescent cells
(—2—3% of total), this value increases to 4—6% upon
exposure of the cells to Oxo-M, whereas no statistically
significant increase in immunoreactivity associated
with either G0, or G4 (of which 14% of the cellular
complement is localized to V1) was observed for the
same fraction. A similar agonist-induced translocation
of the a subunits of G~1and G11 has previously been
reported for Chinese hamster ovary cells transfected
with the cDNA for the m1 mAChR (Svoboda and
Milligan, 1994), although in the latter study an ago-
nist-induced translocation of G,~,was also observed.
The endocytosis of Guq and G1~ in SH-SY5Y cells in
response to Oxo-M addition could indicate either a
functional role for the G protein in the sustained cou-
pling of internalized mAChRs to PLC or, alternatively,
the intracellular targeting of these subunits before lyso-
somal degradation. Consistent with the latter possibil-
ity is the observation that Guq, Gui1, and mAChRs
all undergo down-regulation in response to chronic
mAChR activation, whereas G~1.is much less affected
(Fig. 2B). The reductions in G,~q/Go11immunoreactiv-
ity (49—71%) were similar in magnitude to the loss
of mAChRs (52%; see legend to Fig. 2). This observa-
tion is consistent with previous studies that indicate
that both PLC-coupled wild-type receptors and Gq un-
dergo down-regulation at approximately the same rate
(Milligan et al., 1996). Relatively little functional PLC
activity (—-5% of total) was recovered in the V1 frac-
tion and western blot analysis confirmed the relative
deficiency of the isoform of PLC (131), which is con-
sidered to be primarily linked to Goq/G,~ii.Unexpect-
edly, however, appreciable PLC-/33 and PLC-yl im-
munoreactivity was found to be associated with the V1
fraction. Although the significance of the latter finding
is presently unclear, the results could suggest that PLC
functional activity is highly regulated in this fraction.
In contrast to the results obtained for Guq and Gui1, no
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translocation of any of these three isoforms of PLC into
the V1 fraction was observed after agonist addition.
Although neither G,,q/G11it nor PLC-/31 is abundant
in V1, substantial increases in DAG mass and ~
32P]PA
labeling are observed in this fraction after agonist pre-
treatment of cells. Moreover, a significant proportion
of the newly formed [32P]PA is of a tetraenoic species,
suggesting that the DAG backbone is derived from an
inositol lipid. Although these data could be interpreted
as evidence in favor of the ability of internalized
mAChRs to continue to hydrolyze phosphoinositides,
two lines of evidence challenge a functional role for
sequestered mAChRs. First, the increases in [32P]PA
labeling persist under hypertonic conditions in which
mAChR translocation is prevented (see Fig. 6). Sec-
ond, increases in [32PIPA labeling (t
112 = 2 mm) occur
beft.re the endocytosis of the mAChR (t112 = 12 mm).
Thus, it is more likely that DAG formation occurs
primarily at a site other than the V1 fraction (presum-
ably the plasma membrane) and that a redistribution
of at least some of this lipid to the endosomal compart-
ment (and its phosphorylation to PA) occurs thereafter.
Although increases in phosphoinositide hydrolysis
may occur primarily at subcellular location(s) other
than the V1 fraction, the products of phosphoinositide
turnover may nonetheless play an important role in
the intracellular trafficking of mAChRs. For example,
increases in DAG concentration have been demon-
strated to promote membrane fusion (Siegel et al.,
1989; Sánchez-Migallón et a!., 1994). Furthermore,
the formation of PIP has also been linked to membrane
fusion and intracellular trafficking events (Del Vecchio
and Pilch, 1991).
We have previously calculated that for continuous
mAChR-stimulated phosphoinositide hydrolysis to oc-
cur in SH-SY5Y cells, the entire PIP2 pool must be
replenished every 45—60 s (Fisher et al., 1994). This
prompted an examination of the ability of the V1 frac-
tion to synthesize phosphoinositides. Although all of
the enzymes necessary for the breakdown and resyn-
thesis of inositol lipids can be detected, the most pro-
nounced observation was the relative inability of the
V1 fraction to synthesize PIP2, as was apparent from
both
32P-labeling studies and direct enzyme measure-
ment. Because PIP formation occurs readily in this
fraction, precursor availability is unlikely to be a rate-
limiting factor in PIP
2 synthesis. In addition, because
PIP kinase activity in SH-SY5Y cells is recovered pre-
dominantly in the particulate fractions (as previously
observed for C6 glioma cells; see Morris et al., 1990),
it is unlikely that, in the intact cell, the cytosol would
provide a significant source of the enzyme. Accord-
ingly, it is conceivable that the limited ability of the
V fraction to synthesize PIP2 may represent one of
the key factors that prevents the sustained coupling of
endocytosed mAChRs to PLC. The low activities of
both PIP and DAG kinases in the V1 fraction, along
with the enrichment of P1 kinase, is strikingly reminis-
cent of the distribution of these same enzymes in glu-
cose transporter—containing vesicles and clathrin-
coated vesicles (Campbell et al., 1985; Del Vecchio
and Pilch, 1991) and raises the possibility that this
enzyme profile may be functionally relevant in struc-
tures dedicated to intracellular trafficking.
In summary, although all components necessary for
operation of the phosphoinositide cycle can be detected
in the endocytic fraction into which mAChRs are endo-
cytosed, the major conclusion to emanate from the
present study is that once internalized, mAChRs appear
to possess little, if any, potential to further activate
PLC. One factor that may explain the refractoriness of
internalized receptors to activate PLC is the very lim-
ited capacity of this endocytic fraction to synthesize
the primary lipid substrate PIP2.
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